GRML Stock Catalyst: Klotho Neurosciences Advances Manufacturing of ALS Gene Therapy

Jun 30, 2025 · 4:03am ET

Company progresses towards clinical trials for amyotrophic lateral sclerosis treatment.

Max move

+78.8%

High of day $1.39

Sparker timei

4:03am ET

GRML · Jun 30, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Klotho Neurosciences announced the progression of its manufacturing process for a gene therapy aimed at treating amyotrophic lateral sclerosis (ALS). This development marks a significant step towards initiating clinical trials for the novel treatment.

The company did not disclose specific timelines or additional details regarding the manufacturing process or the forthcoming clinical trials.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GRML sparks.

Download Sniper App →

Catch the next GRML-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →